| Autor: |
Oladipo, Elijah Kolawole, Akinleye, Temitope Michael, Adeyemo, Stephen Feranmi, Akinboade, Modinat Wuraola, Siyanbola, Kehinde Favour, Adetunji, Victoria Ademide, Arowosegbe, Olukayode Abimbola, Olatunji, Victoria Kehinde, Adaramola, Esther Oluwadarasimi, Afolabi, Hezekiah Omotayo, Ajani, Christianah Damilola, Siyanbola, Taiwo Pleasure, Folakanmi, Elizabeth Oluwatoyin, Irewolede, Boluwatife Ayobami, Okesanya, Olalekan John, Ajani, Olumide Faith, Ariyo, Olumuyiwa Elijah, Jimah, Esther Moradeyo, Iwalokun, Bamidele Abiodun, Kolawole, Olatunji Matthew |
| Předmět: |
|
| Zdroj: |
In Silico Pharmacology; 7/24/2024, Vol. 12 Issue 2, p1-17, 17p |
| Abstrakt: |
Epstein–Barr Virus (EBV), structurally similar to other herpes viruses, possess significant global health challenges as it causes infectious mononucleosis and is also associated with various cancers. Due to this widespread impact, an effective messenger RNA (mRNA) vaccine is paramount to help curb its spread, further underscoring the need for its development. This study, following an immunoinformatic approach, aimed to design a comprehensive mRNA vaccine against the EBV by selecting antigenic proteins, predicting Linear B-cell epitopes, cytotoxic T-cell lymphocyte (CTL) and helper T-cell lymphocyte (HTL) epitopes, and assessing vaccine characteristics. Seventy-nine EBV isolates from diverse geographical regions were examined. Additionally, the vaccine construct's physicochemical properties, transmembrane domains, solubility, and secondary structures were analysed. Molecular docking was conducted with Toll-Like Receptor 5 (TLR-5). Population coverage was assessed for selected major histocompatibility complex (MHC) alleles, and immune response was simulated. The result of this study highlighted a vaccine construct with high antigenicity, non-toxicity, and non-allergenicity and possessed favourable physicochemical properties. The vaccine's 3D structure is native-like and strongly binds with TLR-5, indicating a solid affinity with TLR-5. The selected MHC alleles provided broad universal population coverage of 89.1%, and the immune simulations suggested a robust and wide-ranging immunogenic response, activating critical immune cells, antibodies, and cytokines. These findings provide a solid foundation for further development and testing of the EBV candidate vaccine, offering potential solutions for combating EBV infections. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink